“Ruby” is a family of structurally related ingredients with applications in food, personal care and other markets. The identity of the Ruby family is not yet public.

In 2012, Evolva partnered certain ingredients in the Ruby family with Roquette (Lestrem, France). The partnership involves pathway creation, strain improvement and scale-up. Roquette has exclusivity for certain ingredients within the Ruby family, whilst Evolva retains all rights to others.

The partnership has progressed well, with all milestones achieved on or ahead of plan. After delivering an initial yeast strain in May 2015, Evolva provided Roquette with a final, improved version in the autumn of 2015. This should enable a leaner and more efficient fermentation route to the target food ingredient. The improved strain exceeds the predefined productivity goals by between 10% and 65%. Roquette is responsible for the further steps towards commercial production. The final milestone triggered a payment, based on the value added by Evolva’s production route, of CHF 1.2 million.

After the completion of the Roquette project, Evolva is now internally pursuing the development of an additional ingredient. This additional ingredient is aimed at a very different application area, but derives from a pathway, related to Roquette’s target product. Whilst early, the development builds upon the high performance strains developed during the collaboration with Roquette.

  • Biotech in your vanilla ice cream ?

    The Motley Fool is one of those very rare members of the media that still have fun doing good financial analysis, business reporting, and contrarian journalism.

    The Motley Fool
More articles

Sign up to receive our
Press Releases!

Sign up